401 Professional Drive, Suite 280
43 articles about Sirnaomics, Inc.
Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer
Sirnaomics, Inc. today announced dose administration for the first patient in a Phase 2b study of the company's drug candidate, STP705, for the treatment of squamous cell skin cancer in situ (isSCC).
Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer
Sirnaomics, Inc. announced today dose administration for the first patient in a Phase 1 U.S. clinical study for liver cancer treatment.
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
Sirnaomics, Inc., today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company's lead candidate, STP705, for the treatment of skin squamous cell carcinoma in situ (isSCC).